<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00534625</url>
  </required_header>
  <id_info>
    <org_study_id>CTI-04-C07-202</org_study_id>
    <nct_id>NCT00534625</nct_id>
  </id_info>
  <brief_title>Assessment of PFT, Safety, and PK of Zileuton Injection in Asthma Patients</brief_title>
  <official_title>Phase 2 Study of the Assessment of Pulmonary Function, Safety, Tolerability, and PK of Zileuton Injection in Patients With Chronic Stable Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Critical Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Critical Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single intravenous injection of zileuton (150 or 300 mg) will be administered to patients
      with stable asthma. The goals will be to determine if zileuton i.v. can produce a rapid
      increase in FEV1/PEFR and when this effect can be seen. The safety of this route of
      administration of zileuton will also be studied. PK will be obtained in a population based
      method.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect on pulmonary function</measure>
    <time_frame>Within 0-12 hours after single dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessments</measure>
    <time_frame>Within 0-36 hours after single dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg zileuton by intravenous injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg zileuton by intravenous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zileuton</intervention_name>
    <description>Single injection of zileuton 150 mg</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Single injection of placebo</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zileuton</intervention_name>
    <description>Single injection of zileuton 300 mg</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients 12 years of age or older

          2. Diagnosis of asthma by current ATS guidelines

          3. FEV1 of 4-80%.

          4. Reversibility of at least 13% after bronchodilator treatment

          5. Must be willing to with hold SABA for 6 hours and ICS for 24 hours prior to treatment.

          6. Informed consent

        Exclusion Criteria:

          1. Females of child bearing potential unless using birth control

          2. Uncontrolled systemic disease

          3. Known hypersensitivity to zileuton or components of zileuton injection.

          4. Upper or lower respiratory tract infection within the last 2 weeks

          5. Admission to hospital or ER visit for asthma exacerbation within the last 3 months

          6. Course of oral or parenteral steroids within the last 3 months

          7. Current smoker or H/O &gt; 15 pack years

          8. Creatinine &gt; 1.5 x ULN

          9. ALT &gt; 3 x ULN

         10. BP &lt; 100 (systolic)

         11. H/O HIV

         12. H/O alcohol or drug abuse

         13. Patients taking Xolair, theophylline, montelukast, zafirlukast, nedocromil, cromolyn
             sodium, Zyflo (within the past 7 days), warfarin, propranolol, inhaled
             anti-cholinergics, or LABA.

         14. Pregnant or breast feeding females

         15. Current participation or participation in an experimental drug study within 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Cees Wortel</last_name>
    <role>Study Director</role>
    <affiliation>Critical Therapeutics</affiliation>
  </overall_official>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2007</study_first_submitted>
  <study_first_submitted_qc>September 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2007</study_first_posted>
  <last_update_submitted>March 19, 2008</last_update_submitted>
  <last_update_submitted_qc>March 19, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2008</last_update_posted>
  <responsible_party>
    <name_title>Cornelis Wortel MD, PhD/Acting CMO</name_title>
    <organization>Clinquest Inc</organization>
  </responsible_party>
  <keyword>Asthma, exacerbation, pulmonary function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zileuton</mesh_term>
    <mesh_term>Hydroxyurea</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

